Barclays analyst Charles Pitman CFA reiterated a Buy rating on UCB SA (0NZT – Research Report) today and set a price target of €240.00. The company’s shares closed last Friday at €188.86.

Copyright © 2025 MarketWatch, Inc. All rights reserved.

Roche already has one Alzheimer’s candidate in its pipeline targeting tau, but has added a second via a deal with Belgian drugmaker UCB worth up to $2 billion. The Swiss pharma group is paying $ ...

Discover the Top 20 best Fashion Logos that define style in the industry! From iconic to innovative, explore how these logos captivate audiences! In fashion, logos are more than just symbols; they are ...

For more control, third-party tools like TranslucentTB and TaskbarTools let users make the taskbar fully transparent or adjust its transparency level. These apps are easy to use, lightweight, and ...